Rabies guidelines

National Institute of Communicable Diseases
Directorate General of Health Services
Ministry of Health & Family Welfare
Government of India
New Delhi
National Guidelines for
Rabies Prophylaxis and
Intra-dermal Administration of
Cell Culture Rabies Vaccines
2007

Contents
1. Introduction 5
2. Post-Exposure Prophylaxis 6
2.1 Decision to Treat 6
2.2 Approach to Post-Exposure Prophylaxis 8
2.2.1 Management of Animal Bite Wound 8
2.2.2 Rabies Immunoglobulins (RIG) 10
2.2.3 Anti-Rabies Vaccines 12
2.2.3.1 Intra-Muscular (IM) Regimen 13
2.2.3.2 Intra-Dermal Rabies Vaccination (IDRV) 14
2.3 Post-Exposure Prophylaxis for Previously Vaccinated Persons 17
3. Pre-Exposure Vaccination 18
4. Decision Tree: Guide to Post-Exposure Prophylaxis (PEP) 19
List of Experts 20

MESSAGE
Rabies continues to be a public health problem in India. The exact magnitude
of animal bites in the country is not reliably known though some studies have
estimated it to be as high as 17 million per annum. Government of India has
banned the production and use of Nervous Tissue Vaccine (NTV) in December,
2004 which was the vaccine widely used in the public sector. With the stoppage
of NIV, the availability and affordability of modern Cell Culture Vaccine became
a major issue with many States. With the recommendations of WHO, National
experts and ICMR study on the use of intradermal vaccines, National Regulatory
Authority has permitted the use of this economical and efficacious route in India
also. To operationalise the implementation of id route there was an urgent need
to develop national guidelines for ID implementation, NICD convened expert
group meeting and framed these guidelines.
I congratulate Director, NICD and his team for bringing out these guidelines.
I am very optimistic that these guidelines will be extremely useful to the States to
address the issue of use of Anti-Rabies Vaccine.
(Dr. R.K. Srivastava)
Dr. R.K. SRIVASTAVA
M.S. (Ortho) D.N.B. (PMR)
DIRECTOR GENERAL
Hkkjr ljdkj
LokLF; lsok egkfuns’kky;
fuekZ.k Hkou] ubZ fnYyh&110011
GOVERNMENT OF INDIA
DIRECTORATE GENERAL OF HEALTH SERVICES
NIRMAN BHAVAN, NEW DELHI - 110011
TEL. No.: 91-11-23061438, 23061063
FAX NO. : 91-11-23061924
E-mail: dghs@nic.in

4 National Guidelines for Rabies Prophylaxis and Intra-dermal
Administration of Cell Culture Rabies Vaccines
Preface
Rabies continues to be a major public health problem killing an estimated 20,000
people in India annually. This virtually cent percent fatal disease is nearly hundred
percent preventable by timely and appropriate post-exposure treatment.
Based on vaccine utilisation approximately 3 million people receive post-exposure
treatment in the country. Production and use of reactogenic Nervous Tissue
Vaccine has been stopped since December 2004. Modern, safe and effective
anti-rabies Cell Culture Vaccines (CCVs) are being used for post-exposure
prophylaxis. Higher cost and limited availability are limiting factors for its wider
use. To overcome these problems, WHO recommended the use of intra-dermal
(ID) route of administration of CCVs which not only reduces the cost of post-
exposure prophylaxis but also allows wider coverage in available quantity of
vaccines.
Considering the recommendations of experts, results of clinical trials and
international experience Drug Controller General of India approved the use of
ID route of administration of CCVs in February 2006. However, need was felt to
have revised guidelines for animal bite management including correct technique
of intra-dermal inoculation of CCVs for its easier and wider implementation. An
expert group meeting was held at NICD, Delhi to formulate the guidelines. The
participants in the meeting included practitioners managing anti-rabies clinics,
laboratory medicine practitioners, policy makers, public health experts and
vaccine producers from both public and private sector. The guidelines, which
emerged out of consensus deliberations of the expert group, have been brought
out in this publication.
It is sincerely hoped that the publication will be of immense use for managing
the animal bites and using ID route of inoculation of CCVs. The financial help
received from WHO for this publication is thankfully acknowledged.
Dr Shiv Lal
Addl DG & Director
NICD, Delhi

5National Guidelines for Rabies Prophylaxis and
Intra-dermal Administration of Cell Culture Rabies Vaccines
Rabies is an acute viral disease which causes fatal encephalomyelitis in virtually
all the warm blooded animals including man. The virus is found in wild and some
domestic animals, and is transmitted to other animals and to humans through
their saliva (i.e. bites, scratches, licks on broken skin and mucous membrane).
In urban areas, the disease is mainly transmitted by dogs, being responsible for
about 96% of animal bite cases.
Rabies has terrified man since antiquity. The fear is by no means unfounded since
the disease is invariably fatal and perhaps the most painful and horrible of all
communicable diseases in which the sick person is tormented at the same time
with thirst and fear of water (hydrophobia). Fortunately, animal bites, if managed
appropriately and timely the disease is preventable to a large extent. In this regard
the post-exposure treatment of animal bite cases is of prime importance.
An expert group meeting for reviewing and finalising the guidelines
for management of animal bite cases was held at National Institute of
Communicable Diseases, Delhi. Following this, the national guidelines for
management of animal bites were formulated in 2002 to bring out uniformity
in post-exposure prophylaxis practices. Until recently the Nervous Tissue
Vaccine (NTV) was the mainstay for post-exposure prophylaxis. As per WHO
recommendations, the production and use of this reactogenic vaccine has
been stopped since December 2004 in our country. Modern Cell Culture
Vaccines (CCV) are now being used for post-exposure prophylaxis. Higher cost
of intra-muscular administration of CCV is a limiting factor for its wider use.
To overcome this problem, WHO has recommended use of efficacious, safe
and feasible intra-dermal (ID) route of inoculation of CCVs. Sri Lanka, Thailand
and Philippines have successfully adopted ID route of administration of CCV
against rabies as part of their policy. Clinical trials conducted in India have
proved intra-dermal route to be safe, efficacious and feasible for use in the
country. National authorities after expert consultation have approved the use of
ID route for administration of CCVs in the country in phased manner. Hence,
the guidelines of animal bite management have been reviewed and revised with
inclusion of correct technique of ID inoculation of anti-rabies CCVs.
1
Introduction

2
Post-Exposure Prophylaxis (PEP)
2.1 Decision to treat
In rabies endemic country like India, where every animal bite is potentially
suspected as a rabid animal bite the treatment should be started immediately.
Because of long incubation period, which is typical of most cases of human
rabies, it is possible to institute prophylactic post-exposure treatment. This must
be started at the earliest to ensure that the individual will be immunised before
the rabies virus reaches the nervous system. However, people who present for
treatment even months after a possible rabies exposure should be evaluated and
treated as if the event had occurred recently.
To bring out uniformity globally, the classification of animal bite for post-exposure
prophylaxis has been based on WHO recommendations (Table 1).
Table 1: Type of contact, exposure and recommended
post-exposure prophylaxis
Category Type of contact Type of
exposure
Recommended post-exposure
prophylaxis
I Touching or feeding of animals
Licks on intact skin
None • None, if reliable case history
is available
II Nibbling of uncovered skin
Minor scratches or abrasions
without bleeding
Minor • Wound management
• Anti-rabies vaccine
III Single or multiple transdermal
bites or scratches, licks on
broken skin
Contamination of mucous
membrane with saliva (i.e. licks)
Severe • Wound management
• Rabies immunoglobulin
• Anti-rabies vaccine

Vaccination status of the biting animal: Although unvaccinated animals are
more likely to transmit rabies, vaccinated animals can also do so if the vaccination
of the biting animal was ineffective for any reason. A history of rabies vaccination
in an animal is not always a guarantee that the biting animal is not rabid. Animal
vaccine failures may occur because of improper administration or poor quality of
the vaccine, poor health status of the animal, and the fact that one vaccine dose
does not always provide long-lasting protection against infection in dogs.
Provoked versus unprovoked bites: Whether a dog bite was provoked rather
than unprovoked should not be considered a guarantee that the animal is
not rabid as it can be difficult to understand what an attacking dog considers
provocation for an attack.
Observation of biting animal: The treatment should be started immediately
after the bite. The treatment may be modified if animal involved (dog or cat)
remains healthy throughout the observation period of 10 days by converting
post-exposure prophylaxis to pre-exposure vaccination by skipping the vaccine
dose on day 14 and administering it on day 28 while using Essen Schedule. The
observation period is valid for dogs and cats only. The natural history of rabies
in mammals other than dogs or cats is not fully understood and therefore the
10-day observation period may not be applicable.
Bite by wild animals: Bite by all wild animals should be treated as category III
exposure.
Bite by rodents: It should be noted that bites by domestic rats, mice, squirrel,
hare and rabbits seldom require treatment.
Bat rabies: Bat rabies has not been conclusively proved in India and hence
exposure to bats does not warrant treatment.
Special circumstances: Pregnancy, lactation, infancy, old age and concurrent
illness are no contra indications for rabies post-exposure prophylaxis in the
event of an exposure. Post-exposure prophylaxis against rabies takes preference
over any other consideration since it is a life saving procedure. Moreover,
rabies vaccine does not have any adverse effect on fetus, mother-to-be and the
course of pregnancy. Hence complete post-exposure treatment should be given
depending on the category of the exposure.
Post-exposure prophylaxis of immuno compromised patients: Several
studies of patients with HIV/AIDS have reported that those with low CD4
(<200 counts) will mount a significantly lower or no detectable neutralising
antibody response to rabies. In such patients and those in whom the presence
of immunological memory is no longer assured as a result of other causes,
proper and thorough wound management and antisepsis accompanied by

local infiltration of rabies immunoglobulins followed by anti-rabies vaccination
are of utmost importance. Even immuno compromised patients with
category II exposures should receive rabies immunoglobulin in addition to a
full post-exposure vaccination. Preferably, if the facilities are available, anti-
rabies antibody estimation should be done 10 days after the completion of
course of vaccination.
Human-to-human transmission: The risk of rabies transmission to other
humans from a human rabies case is very minimal and there has never been
a well documented case of human-to-human transmission, other than the
few cases resulting from organ transplant. However, people who have been
exposed closely to the secretions of a patient with rabies may be offered PEP as
a precautionary measure.
It is reemphasised that treatment should be started as early as possible
after exposure. However, it should not be denied to person reporting late for
treatment as explained previously.
2.2 Approach to Post-Exposure Prophylaxis (PEP)
The post-exposure prophylaxis is a three pronged approach. All three carry equal
importance and should be done simultaneously as per the category of the bite
(4. Decision tree: Guide to Post-Exposure Prophylaxis).
 Management of animal bite wound
 Passive immunisation: Rabies Immunoglobulins (RIG)
 Active immunisation: Anti-Rabies Vaccines (ARV)
2.2.1 Management of animal bite wound
Wound toilet: Since the rabies virus enters the human body through a bite or scratch,
it is imperative to remove as much saliva, and thereby the virus, from the wound as is
possible by an efficient wound toilet that should not involve additional trauma. Since
the rabies virus can persist and even multiply at the site of bite for a long time, wound
toilet must be performed even if the patient reports late. (Table 2)
This can be done by prompt and gentle thorough washing with soap or detergent
and flushing the wound with running water for 10 minutes. If soap and detergent
are not immediately available wash with running water for at least 10 minutes.
Avoid direct touching of wounds with bare hands. Considering the importance of
this step the anti-rabies clinics should have wound washing facilities.
The application of irritants (like chilies, oil, turmeric, lime, salt, etc) is unnecessary
and damaging. In case irritants have been applied on the wound, enough gentle
washing with soap or detergent to remove the extraneous material especially
oil should be done followed by flushing with copious amount of water for 10
minutes immediately.

It should be noted that the immediate washing of the wound is a priority. However,
the victim should not be deprived of the benefit of wound toilet as long as there
is an unhealed wound which can be washed even if the patient reports late.
The maximum benefit of the wound washing is obtained when fresh wound is
cleaned immediately.
Application of antiseptics: After thorough washing and drying the wound,
any one of the available chemical agents should be applied viz Povidone iodine
(Betadine), Alcohol, Chloroxylenol (Dettol), Chlorhexidine Gluconate and
Cetrimide solution (Savlon - in appropriate recommended dilution), etc.
Table 2: Wound Management
Do’s
Physical Wash with running tap water Mechanical removal of virus from
the wound
Chemical Wash the wound with soap and water
Apply disinfectant
Inactivation of the virus
Biological Inﬁltrate immunoglobulins in the depth and around
the wound in Category III exposures
Neutralisation of the virus
Don’ts
• Touch the wound with bare hand
• Apply irritants like soil, chilies, oil, herbs, chalk, betel leaves etc.

Local infiltration of rabies immunoglobulins: In category III bites rabies
immunoglobulins should be infiltrated in the depth and around the wound to
inactivate the locally present virus as described below.
Suturing of wound should be avoided as far as possible. If surgically unavoidable,
minimum loose sutures should be applied after adequate local treatment along
with proper infiltration of rabies immunoglobulins.
Cauterisation of wound is no longer recommended as it leaves very bad scar,
and does not confer any additional advantage over washing the wound with
water and soap.
Injection tetanus toxoid should be given to the un-immunised individual.
To prevent sepsis in the wound, a suitable course of an antibiotic may be
recommended.
2.2.2 Rabies Immunoglobulins (RIG)
The anti-rabies serum/rabies immunoglobulin provides passive immunity in
the form of ready-made anti-rabies antibody to tide over the initial phase of the
infection. Anti-rabies serum or RIG has the property of binding with the rabies
virus, thereby resulting in the loss of infectivity of the virus.
Two types of RIGs are available:
Equine Rabies Immunoglobulins (ERIG): ERIG is of heterologous origin raised
by hyper-immunisation of horses. However, currently manufactured ERIGs are
highly purified and the occurrence of adverse events has been significantly
reduced. Still these should be administered after sensitivity test.
Human Rabies Immunoglobulins (HRIG): HRIG are free from the side effects
encountered in a serum of heterologous origin, and because of their longer half
life, are given in half the dose of equine anti-rabies serum.
The anti-rabies sera should always be brought to room temperature (20 – 25ºC)
before use.
Dose of rabies immunoglobulins: The dose of equine rabies immunoglobulins
is 40 IU per kg body weight of patient and is given after testing for sensitivity, upto
a maximum of 3000 IU. The ERIG produced in India contains 300 IU per ml. The
dose of the human rabies immunoglobulins (HRIG) is 20 IU per kg body weight
(maximum 1500 IU). HRIG does not require any prior sensitivity testing. HRIG
preparation is available in concentration of 150 IU per ml.
Administration of immunoglobulins: As much of the calculated dose of RIG
as is anatomically feasible should be infiltrated into and around the wounds.

Multiple needle injections into the wound should be avoided. Remaining, if
any, after all wounds have been infiltrated, should be administered by deep
intramuscular injection at an injection site distant from the vaccine injection
site. Animal bite wounds inflicted can be severe and multiple, especially in
small children. In such cases, the calculated dose of the rabies immunoglobulin
may not be sufficient to infiltrate all wounds. In these circumstances, it is
advisable to dilute the immunoglobulins in sterile normal saline 2 to 3 fold
to be able to permit infiltration of all wounds. The total recommended dose
of immunoglobulin must not be exceeded as it may suppress the antibody
production by the vaccine.
If immunoglobulin was not administered when vaccination was begun, it can
be administered upto the seventh day after the administration of the first
dose of vaccine. Beyond the seventh day, Rabies Immunoglobulin (RIG) is not
indicated since an antibody response to anti-rabies vaccine is presumed to
have occurred.
Immunoglobulin should never be administered in the same syringe or at the
same anatomical site as vaccine.
Sensitivity test before administration of ERIG: With antisera of equine
origin, anaphylactic shock may occur and thus sensitivity testing is mandatory
before giving ERIG. Skin test may be performed as per the manufacturers
instructions given in the product insert. Otherwise general guidelines are
described in Table 3.
Table 3: Skin testing prior to administration of ARS/ERIG
 Inject 0.1 ml ERIG diluted 1:10 in physiological saline intra-dermally into the flexor surface of the
forearm to raise a bleb of about 3-4 mm diametre.
 Inject an equal amount of normal saline as a negative control on the flexor surface of the other forearm
 After 15 minutes an increase in diametre to > 10 mm of induration surrounded by flare is taken as
positive skin test, provided the reaction on the saline test was negative.
 An increase or abrupt fall in blood pressure, syncope, hurried breathing, palpitations and any other
systemic manifestations should be taken as positive test
A negative skin test must never reassure the physician that no anaphylactic
reaction will occur. Those administering ERIG should always be ready to treat early
anaphylactic reactions with adrenalin. The dose is 0.5 ml of 0.1 percent solution
(1 in 1000, 1mg/ml) for adults and 0.01 ml/kg body weight for children, injected
subcutaneously or IM. If patient is sensitive to ERIG, HRIG should be used.
Approach to a patient requiring rabies immunoglobulin when none is
available: In circumstances where no immunoglobulin are available greater
emphasis should be given to proper wound toileting followed by Essen Schedule of

Cell Culture Vaccine with double dose on day 0 at 2 different sites intramuscularly
(0 day – 2 doses on left and right deltoid, 3, 7, 14 and 28 days). It is emphasised
that doubling the first dose of CCV is not a replacement to RIG. A full course of
vaccine should follow thorough wound cleansing and passive immunisation.
Tolerance and side effects: With RIG, there may be transient tenderness at
the injection site and a brief rise in body temperature which do not require
any treatment. Skin reactions are extremely rare. RIG must never be given
intravenously since this could produce symptoms of shock, especially in patients
with antibody deficiency syndromes.
Serum sickness occurs in 1% to 6% of patients usually 7 to 10 days after injection
of ERIG, but it has not been reported after treatment with HRIG.
2.2.3 Anti-Rabies Vaccines
Active immunisation is achieved by administration of safe and potent CCVs. In
India, NTV was used for post-exposure treatment in public sector. However, as
this vaccine was reactogenic, the production was stopped in December, 2004.
CCVs are now used for active immunisation.
Indications: All age groups of animal bite victims of Category II and III require
the same number of injections and dose per injection. The Category III
exposures, in addition require administration of rabies immunoglobulins as
discussed earlier.
Storage and transportation: Though most Cell Culture Vaccines are marketed in
freeze dried (lyophilised) form which is more tolerant of vagaries of temperature,
yet it is recommended that these vaccines should be kept and transported at a
temperature range of 2-8ºC. Freezing does not damage the lyophilised vaccine
but there are chances of breakage of ampoule containing the diluent. Liquid
vaccines should never be frozen.
Reconstitution and storage: The lyophilised vaccine should be reconstituted
with the diluent provided with the vaccine immediately prior to use. However,
in case of unforeseen delay it should not be used after 6-8 hours of
reconstitution.
Adverse effects with Cell Culture Vaccines: The Cell Culture Vaccines are widely
accepted as the least reactogenic rabies vaccines available today. However, few
studies have now shown that adverse effects can be either general in nature or
allergic in origin. The general adverse reactions include sore arm, headache,
malaise, nausea, fever and localised oedema at the site of injection. Symptomatic
treatment may be needed.

Switch over from one brand/type of vaccine to the other: Shifting from
one brand/type of CCV to other brand/type should not be encouraged as
literature supports that good immunity is best achieved with same brand.
However under unavoidable circumstances, available brand/type may be
used to complete PEP.
Protective level of anti-rabies antibody: Humoral antibodies play important
role in protection against rabies and a titre of 0.5 IU/ml or more in serum as
tested by Rapid Fluorescent Focus Inhibition Test (RFFIT) is considered as
protective.
Currently available CCVs could be administered by IM regimen or approved CCVs
could be administered by ID regimen.
2.2.3.1 Intra-muscular (IM) Regimen
The currently available vaccines and regimen in India for IM administration are
described below.
Vaccines
1. Cell Culture Vaccines
 Human Diploid Cell Vaccine (HDCV): Produced locally in private
sector
 Purified Chick Embryo Cell Vaccine (PCEC): Produced locally in private
sector
 Purified Vero Cell Rabies Vaccine (PVRV): Imported and produced locally
in public & private sector
2. Purified Duck Embryo Vaccine: Produced locally in private sector
Regimen
Essen Schedule:Fivedoseintramuscularregimen-Thecourseforpost-exposure
prophylaxis should consist of intramuscular administration of five injections
on days 0, 3, 7, 14 and 28. The sixth injection (D90) should be considered
as optional and should be given to those individuals who are immunologically
deficient, are at the extremes of age and on steroid therapy. Day 0 indicates date
of first injection.
Site of inoculation: The deltoid region is ideal for the inoculation of these
vaccines. Gluteal region is not recommended because the fat present in this
region retards the absorption of antigen and hence impairs the generation of
optimal immune response. In case of infants and young children antero-lateral
part of the thigh is the preferred site.

2.2.3.2 Intra-dermal (ID) Regimens
Concept of intra-dermal inoculation of anti-rabies vaccines (IDRV): Intra-
dermal regimens consist of administration of a fraction of intramuscular dose
of certain rabies vaccine on multiple sites in the layers of dermis of skin. The
vaccines used are same; however route, dose and site of administration differ.
The use of intra-dermal route leads to considerable savings in terms of total
amount of vaccine needed for full pre- or post- exposure vaccination, thereby
reducing the cost of active immunisation. Single dose (0.5ml/1ml) of rabies
vaccine/antigen when given by IM route gets deposited in the muscles. There
after the antigen is absorbed by the blood vessels and is presented to antigen
presenting cells which triggers immune response. Whereas, while using ID route,
small amount (0.1ml) of rabies vaccines/antigen is deposited in the layers of the
skin at multiple sites. The antigen is directly presented to the antigen presenting
cells (with out circulation/dilution in blood) at multiple sites triggering a stronger
immune response.
Mechanism of action of IDRV: Intra-dermal inoculation is deposition of
approved rabies vaccine (or antigen) in the layers of dermis of skin. Subsequently
the antigen is carried by antigen presenting cells via the lymphatic drainage to
the regional lymph nodes and later to the reticulo-endothelial system eliciting a
prompt and highly protective antibody response. Immunity is believed to depend
mainly upon the CD 4 + T-cell dependent neutralising antibody response to the
G protein. In addition, cell-mediated immunity has long been reported as an
important part of the defense against rabies. Cells presenting the fragments
of G protein are the targets of cytotoxic T- cells and the N protein induced T
helper cells. The immune response induced by IDRV is adequate and protective
against rabies.
General guidelines for use of IDRV
 Vaccines to be applied by intra-dermal route of administration should be
approved by DCGI.
 The vaccine package leaflet should include a statement indicating that the
potency as well as immunogenicity and safety allow safe use of vaccine by
ID pre- and post-exposure.
 Post Marketing Surveillance (PMS) data should be maintained for minimum
of two years by vaccine manufacturers on a pre-designed and approved
protocol.
 Intra-dermal injections must be administered by staff trained in this
technique.
 Vaccine vials must be stored at 2º to 8ºC after reconstitution.
 The total content of reconstitute vial should be used as soon as possible,
but at least with in 8 hours.
 All the reconstituted vaccines should be discarded after 8 hours of
reconstitution and at the end of the day

 Rabies vaccines formulated with an adjuvant should not be administered
intra-dermally.
 Vaccine when given intra-dermally should raise a visible and palpable bleb in
the skin.
 In the event that the dose is inadvertently given subcutaneously or
intra-muscularly or in the event of spillage, a new dose should be given
intradermally in near by site.
 Animal bite victims on chloroquine therapy (anti-malarial therapy) should be
given ARV by intramuscular route.
Vaccines and regimen approved for ID use in the country
Considering the recommendations on intra-dermal application of rabies by
WHO and results of safety, efficacy and feasibility trials conducted in India,
Drug Controller General of India (DCGI) approved the use of reduced dosage
intra-dermal vaccination regimen for rabies post-exposure prophylaxis. The
use of this route leads to considerable savings in terms of the total amount of
vaccine needed for a full post-exposure vaccination, thereby reducing the cost
of active immunisation.
The following have been approved by DCGI currently for use by intra-dermal
route. Vaccines
PVRV – Verorab, Aventis Pasteur (Sanofi Pasteur) India Pvt. Ltd.
PCECV – Rabipur, Chiron Behring Vaccines Pvt. Ltd.
PVRV – Pasteur Institute of India, Coonoor
PVRV – Abhayrab, Human Biologicals Institute.
Potency of approved vaccines: The vaccines should have stated potency of >
2.5 IU per IM dose, irrespective of reconstituted volume. The same vaccine is
used for ID administration as per stated schedule. 0.1ml of vaccine, irrespective
of reconstituted volume, is administered per ID site as per schedule below.
Regimen
Updated Thai Red Cross Schedule (2-2-2-0-2).
This involves injection of 0.1ml of reconstituted vaccine per ID site and on two
such ID sites per visit (one on each deltoid area, an inch above the insertion
of deltoid muscle) on days 0, 3, 7 and 28. The day 0 is the day of first dose
administration of IDRV and may not be the day of rabies exposure/animal bite.
Maintenance of vaccine vial in use
 Use aseptic technique to with draw the dose
 Store in a refrigerator at 2ºC to 8ºC
 Reconstituted vaccines should be used as soon as possible or within 6 to 8
hours if kept at 2ºC to 8ºC. All unused reconstituted vaccine at the end of
6-8 hours must be discarded.

Materials required
 A vial of rabies vaccine approved for IDRV and its
diluent.
 2 ml disposable syringe with 24 G needle for
reconstitution of vaccine.
 Disposable 1 ml (insulin) syringe (with graduations
upto 100 or 40 units) with a fixed (28 G) needle
(Fig.1)
 Disinfectant swabs (e.g. 70% ethanol, isopropyl
alcohol) for cleaning the top of the vial and the
patients’ skin.
ID injection technique
Using aseptic technique, reconstitute the vial of freeze-dried vaccine with the
diluent supplied by the manufacturer. With 1 ml syringe draw 0.2 ml (up to 20
units if a 100 units syringe is used or upto 8 units if a 40 units syringe is used)
of vaccine needed for one patient (i.e. 0.1 ml per ID site X 2 sites) and expel
the air bubbles carefully from the syringe thereby removing any dead space in
the syringe.
Using the technique of BCG inoculation, stretch the surface of the skin and
insert the tip of the needle with bevel upwards, almost parallel to the skin surface
(Fig.2) and slowly inject half the volume of vaccine in the syringe (i.e. 0.1ml;
either 10 or 4 units) into the uppermost dermal layer of skin, over the deltoid
area, preferably an inch above the insertion of deltoid muscle. If the needle is
correctly placed inside the dermis, considerable resistance is felt while injecting
the vaccine. A raised papule should begin to appear immediately causing a peau
d’ orange (orange peel) appearance (Fig.3). Inject the remaining half the volume
of vaccine (i.e. 0.1ml; either 10 or 4 units) on the opposite deltoid area.
If the vaccine is injected too deeply into the skin (subcutaneous), papule is not
seen. Then the needle should be withdrawn and reinserted at an adjacent site
and the ID vaccine given once more.
Materials required
� A vial of rabies vaccine approved for
IDRV and its diluent.
� 2 ml disposable syringe with 24 G
needle for reconstitution of vaccine.
� Disposable 1 ml (insulin) syringe (with
graduations upto 100 or 40 units) with a
fixed (28 G) needle (Fig.1)
� Disinfectant swabs (e.g. 70% ethanol,
isopropyl alcohol) for cleaning the top
of the vial and the patients’ skin.
Fig.1 : 1ml syringe with hypodermic
needle (Insulin syringe)
Using aseptic technique, reconstitute the vial of freeze-dried vaccine with the diluent
supplied by the manufacturer. With 1 ml syringe draw 0.2 ml (up to 20 units if a 100
units syringe is used or upto 8 units if a 40 units syringe is used) of vaccine needed for
one patient (i.e. 0.1 ml per ID site X 2 sites) and expel the air bubbles carefully from the
syringe thereby removing any dead space in the syringe.
Using the technique of BCG inoculation, stretch the surface of the skin and insert the tip
of the needle with bevel upwards, almost parallel to the skin surface (Fig.2) and slowly
inject half the volume of vaccine in the syringe (i.e. 0.1mL; either 10 or 4 units) into the
uppermost dermal layer of skin, over the deltoid area, preferably an inch above the
insertion of deltoid muscle. If the needle is correctly placed inside the dermis,
considerable resistance is felt while injecting the vaccine. A raised papule should begin to
appear immediately causing a peau d’ orange (orange peel) appearance (Fig.3). Inject the
remaining half the volume of vaccine (i.e. 0.1ml; either 10 or 4 units) on the opposite
deltoid area.
If the vaccine is injected too deeply into the skin (subcutaneous), papule is not seen. Then
the needle should be withdrawn and reinserted at an adjacent site and the ID vaccine
given once more.
Fig.2 Insertion of needle for ID
inoculation
Fig. 3 Bleb raised on ID inoculation
Fig.1: 1ml syringe with
hypodermic needle
(Insulin syringe)
Fig.2: Insertion of needle for ID inoculation Fig. 3: Bleb raised on ID inoculation
Materials required
deltoid area.
given once more.
inoculation
Materials required
deltoid area.
given once more.
inoculation

Anti-rabies treatment centres which meet the following criteria may use ID
administration :
 Have adequately trained staff to give ID inoculation of anti-rabies vaccine
 Can maintain cold chain for vaccine storage
 Ensure adequate supply of suitable syringes and needles for ID
administration
 Are adequately well versed in management of open vial and safe storage
practices.
2.3 Post-Exposure Prophylaxis for previously vaccinated
persons
Managing re-exposure following post-exposure treatment with TCV: If re-
exposed, persons who have previously received full post-exposure prophylaxis
(either by IM or ID route) with a potent cell-culture vaccine should now be given
only two booster doses, intramuscularly (0.5ml/1ml)/intra-dermally (0.1 ml at
1 site) on days 0 and 3. Proper wound toilet should be done. Treatment with
RIG is not necessary.
Managing exposure following pre-exposure prophylaxis with TCV: If after
recommended pre-exposure prophylaxis, a vaccinated person is exposed to rabies,
a proper wound toileting should be done and two IM/ID (0.1 ml at 1 site) doses of Cell
Culture Vaccine be given on days 0 and 3. Treatment with RIG is not necessary
Managing re-exposure following post-exposure treatment with NTV: Persons
who have previously received full post-exposure treatment with NTV should be
treated as fresh case and may be given treatment as per merits of the case.

3
Pre-exposure Vaccination
Pre-exposure vaccination may be offered to high risk groups like laboratory
staff handling the virus and infected material, clinicians and persons attending
to human rabies cases, veterinarians, animal handlers and catchers, wildlife
wardens, quarantine officers and travelers from rabies free areas to rabies
endemic areas. Pre-exposure vaccination is administered as one full dose of
vaccine intramuscularly or 0.1 ml intra-dermally on days 0, 7 and either day 21
or 28.
Laboratory staff and others at high continuing risk of exposure should have their
neutralising antibody titres checked every 6 months. If it is less than 0.5 IU/ml a
booster dose of vaccine should be given. Such individuals on getting exposed to
rabies virus after successful pre-exposure immunisation require only two booster
injections of vaccine given on days 0 and 3 without any anti-rabies serum/RIGs.

Rabiesexposure
Potentiallyinfected
material*Monkeys/Cattle/Other
domesticanimals
Dog/Cat
Categoryofexposure
CategoryIIICategoryIICategoryI
Step1
Step2
Step3
Step1
Step3
Step4:Putthedog/catunder
observationfor10days
Dog/Cat:Aliveandhealthy
Convertpost-exposure
treatmenttopre-exposure
prophylaxiswhileusingIM
routei.e.skipvaccineon
day14.Completecourseof
treatmentwhileusingIDIM
route
Dog/Cat:Sick/Dead
CompletePEP
Reliablehistoryavailable
NoYes
Reassureandsendback
CategoryIICategoryIII
Step1
Step3
Step1
Step2
Step3
CategoryIICategoryIII
Step1
Step3
Step1
Step2
Step3
*Potentiallyinfectedmaterial
Consumptionofmilkofrabid
cattle
Closecontactwithsaliva/
secretions/contaminated
materialetc.
Step1:WoundManagement:Washwoundwith
soapandwater-applyantiseptics
Step2:InfiltrateRIGinthedepthandaround
thewound
Step3:Anti-rabiesvaccination
EssenSchedule(IM)ondays0,3,7,14&28
or
UpdatedThaiRedCrossSchedule:0.1on2siteson
days0,3,7&28
4
Decision Tree: Guide to Post-Exposure
Prophylaxis (PEP)

Formulation of National Guidelines for Intra-Dermal
Inoculation of Anti-Rabies Cell Culture Vaccines
List of experts
Dr Shiv Lal
Addl DG & Director
National Institute of
Communicable Diseases
Delhi
Dr RL Ichhpujani
Addl Director & NPO IDSP
Delhi
Dr Veena Mittal
Joint Director & Head
Zoonosis Division
Delhi
Dr Mala Chhabra
Deputy Director
Delhi
Dr D Bhattacharya
Joint Director
Delhi
Dr UVS Rana,
Joint Director
Delhi
Dr NS Dharamsaktu
Deputy Director General
Directorate General of Health
Services
Nirman Bhavan
New Delhi
Dr Inder Prakash
ADG (EPI)
Services
Nirman Bhavan
New Delhi
Dr C Sokhey
Adviser
CDSCO
Nirman Bhavan
New Delhi
Dr A K Harit
CMO
Services
Nirman Bhavan, New Delhi
Dr R N Salhan
Medical Superintendent
Safdarjung Hospital
New Delhi
Dr Dinesh Srivastava
Consultant Medicine
Dr Ram Manohar Lohia Hospital
New Delhi
Dr N K Handa
CMO
Hindu Rao Hospital
New Delhi
Dr Lalita Sharma
Deputy Medical Superintendent
GTB hospital
Delhi
Dr H C Tiwari
Medical Superintendent
Infectious Diseases Hospital
Delhi
Dr M K Sudarshan
Principal
Kempegowda Institute of Medical
Sciences
Bangalore
Dr B J Mahendra
President, Association for
Prevention & Control of Rabies
in India (APCRI)
Mandya Institute of Medical
Sciences, Mandya
Dr S N Madhusudana
Additional Professor
National Institute of Mental
Health and Neurosciences
(NIMHANS)
Bangalore
Dr G Sampath
Medical Ofﬁcer
Incharge, Anti-rabies Treatment
Centre
Institute of Preventive Medicine
Hyderabad
Dr R R Iyer
Director Health Services
Pimpri Chinchiwad Pune
Municipal Corporation
Pune
Dr U C Tyagi
Addl MHO
Municipal Corporation of Delhi
Town Hall
Delhi

Dr Nivedita Gupta
Senior research Officer
Indian Council of Medical
Research
New Delhi
Dr R K B Chowdhary
CMO
GTB Hospital
Delhi
Dr T S Daral
GTB Hospital
Delhi
Dr Rajnish Kumar
CMO
Infectious Diseases Hospital
Delhi
Dr Krishan Kumar
Safdarjung Hospital
New Delhi
Dr K N Gowal
Central Research Institute
Kasauli
Dr Mukul Gaur
Human Biologicals Institute
PO Ooty
Dr Vikram Singh
Medical Adviser
Sanofi Pasteur India Pvt Ltd
New Delhi
Dr Chhavi Sandhu
Sanofi Aventis
Mumbai
Mr Anil Puri
Aventis Pharma
New Delhi
Mr Masood Alam
Country Head India Operations
Novartis Vaccines
Mumbai
Dr Subodh Bhatnagar
Medical Director
Serum Institute of India Ltd
Pune
Mr S Balasubramanium
Head Institutional Business
Novartis Vaccines
Mumbai
Mrs Madhu Kapoor
General Manager
Bharat BioTech
International Ltd.
Hyderabad
Mr Shankar Sahu
Product Manager
Zydus Cadila
Ahmedabad
Dr Sampath Krishnan
Cluster Co-ordinator
CDS, WHO
WR Ofiice
Nirman Bhavan
New Delhi - 110 011

Finalisation of Draft of National Guidelines on Animal Bite
Management and Intra-Dermal Inoculation of Anti-Rabies
Cell Culture Vaccines
List of Experts
Dr Shiv Lal
Addl DG & Director
Delhi
Dr RL Ichhpujani
Addl Director & NPO IDSP
Delhi
Dr Veena Mittal
Joint Director & Head
Zoonosis Division
Delhi
Dr M K Sudarshan
Principal
Kempegowda Institute of Medical
Sciences
Bangalore
Dr B J Mahendra
Professor & Head
Dept of Community Medicine
Mandya Institute of Medical
Sciences
Mandya
Dr S N Madhusudana
Additional Professor
National Institute of Mental
Health and Neurosciences
(NIMHANS)
Bangalore
Dr Mala Chhabra
Deputy Director
Delhi

Designing & Printing:
New Concept Information Systems Pvt. Ltd.
e-mail: nc.communication@gmail.com

Rabies guidelines

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Destacado

Destacado (8)

Similar a Rabies guidelines

Similar a Rabies guidelines (20)

Más de Asha Reddy

Más de Asha Reddy (20)

Último

Último (20)

Rabies guidelines